Episode #21
Why Is AI Governance in Healthcare Moving From Approval to Continuous Assurance?
Approval was the old governance endpoint. Continuous assurance is the new one — and it is becoming a performance-management discipline, not a compliance function. Half of surveyed US healthcare organizations have implemented generative AI, yet only 45% of implementers have quantified a return. Deloitte's enterprise survey exposes a wider gap still: 74% of companies plan to deploy agentic AI within two years, while just 21% report a mature governance model for autonomous agents. Adoption is running ahead of both measurable value and control maturity. This issue synthesises intelligence from seven advisory institutions: BCG, McKinsey, Deloitte, EY, PwC, Accenture, and KPMG. The convergence is unusually tight. Every firm extends governance past the deployment gate into ongoing testing, monitoring, and performance management. BCG's 10-20-70 principle puts the point bluntly — 10% of AI transformation impact comes from algorithms, 20% from technology infrastructure, and 70% from operational and organizational redesign. The reframing that matters most for capital allocation is this: governance and deployment speed are not opposed. BCG reports that standardized, pre-governed deployment routes can compress governed agent setup from weeks to roughly a day — an order-of-magnitude gain. The emerging advantage is not less governance. It is reusable governance. For CEOs and boards, that moves AI oversight out of the policy domain and into performance management, capital allocation, and enterprise control.
